Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Herpes simplex Infection

Free Subscription Articles published in Antiviral Res Retrieve available abstracts of 21 articles: HTML format

Single Articles

May 2023
1. CIVRA A, Costantino M, Ronchi G, Pontini L, et al
   Identification of oxysterol synthetic analogs as a novel class of late-stage inhibitors of herpes simplex virus 2 replication.
   Antiviral Res. 2023;215:105634.
   PubMed     Abstract available
   
   
   
2. PACHOTA M, Grzywa R, Iwanejko J, Synowiec A, et al
   Novel inhibitors of HSV-1 protease effective in vitro and in vivo.
   Antiviral Res. 2023;213:105604.
   PubMed     Abstract available
   
   
   December 2022
3. SURYAWANSHI RK, Patil CD, Wu D, Panda PK, et al
   Putative targeting by BX795 causes decrease in protein kinase C protein levels and inhibition of HSV1 infection.
   Antiviral Res. 2022;208:105454.
   PubMed     Abstract available
   
   
   November 2022
4. QIN Q, Wang Y, Huang X, Jin X, et al
   SHIP-1 affects herpetic simplex keratitis prognosis by mediating CD4(+) T lymphocytes migration through PI3K signaling and transcription factor KLF2 in the cornea.
   Antiviral Res. 2022;207:105424.
   PubMed     Abstract available
   
   
   October 2022
5. FRASSON I, Solda P, Nadai M, Tassinari M, et al
   Quindoline-derivatives display potent G-quadruplex-mediated antiviral activity against herpes simplex virus 1.
   Antiviral Res. 2022 Oct 10:105432. doi: 10.1016/j.antiviral.2022.105432.
   PubMed     Abstract available
   
   
   May 2022
6. TIAN R, Ju F, Yu M, Liang Z, et al
   A potent neutralizing and protective antibody against a conserved continuous epitope on HSV glycoprotein D.
   Antiviral Res. 2022;201:105298.
   PubMed     Abstract available
   
   
   April 2022
7. ALIMBAROVA L, Egorova A, Riabova O, Monakhova N, et al
   A proof-of-concept study for the efficacy of dispirotripiperazine PDSTP in a rabbit model of herpes simplex epithelial keratitis.
   Antiviral Res. 2022 Apr 26:105327. doi: 10.1016/j.antiviral.2022.105327.
   PubMed     Abstract available
   
   
   March 2022
8. IQBAL A, Suryawanshi R, Yadavalli T, Volety I, et al
   Erratum to "BX795 demonstrates potent antiviral benefits against herpes simplex Virus-1 infection of human cell lines" [Antivir. Res. 80 (2020) 104814].
   Antiviral Res. 2022 Mar 22:105293. doi: 10.1016/j.antiviral.2022.105293.
   PubMed    
   
   
   
9. MULLER EE, Maseko DV, Kularatne RS
   Phenotypic and genotypic acyclovir resistance surveillance of genital herpes simplex virus 2 in South Africa.
   Antiviral Res. 2022 Mar 7:105277. doi: 10.1016/j.antiviral.2022.105277.
   PubMed     Abstract available
   
   
   November 2021
10. KONDO H, Koshizuka T, Majima R, Takahashi K, et al
    Characterization of a thiourea derivative that targets viral transactivators of cytomegalovirus and herpes simplex virus type 1.
    Antiviral Res. 2021;196:105207.
    PubMed     Abstract available
    
    
    October 2021
11. UHLIG N, Donner AK, Gege C, Lange F, et al
    Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
    Antiviral Res. 2021;195:105190.
    PubMed     Abstract available
    
    
    
12. MADAVARAJU K, Yadavalli T, Singh SK, Qatanani F, et al
    Prophylactic treatment with BX795 blocks activation of AKT and its downstream targets to protect vaginal keratinocytes and vaginal epithelium from HSV-2 infection.
    Antiviral Res. 2021;194:105145.
    PubMed     Abstract available
    
    
    August 2021
13. ROSE R, Brunnemann AK, Baukmann S, Buhler S, et al
    Antiviral susceptibility of recombinant herpes simplex virus 1 strains with specific polymerase amino acid changes.
    Antiviral Res. 2021 Aug 19:105166. doi: 10.1016/j.antiviral.2021.105166.
    PubMed     Abstract available
    
    
    
14. LLORENTE P, Mejias V, Sastre I, Recuero M, et al
    Matrix metalloproteinase 14 regulates HSV-1 infection in neuroblastoma cells.
    Antiviral Res. 2021;192:105116.
    PubMed     Abstract available
    
    
    
15. SCHANG LM, Hu M, Cortes EF, Sun K, et al
    Chromatin-mediated epigenetic regulation of HSV-1 transcription as a potential target in antiviral therapy.
    Antiviral Res. 2021;192:105103.
    PubMed     Abstract available
    
    
    July 2021
16. LIU Y, Tang Q, Rao Z, Fang Y, et al
    Inhibition of herpes simplex virus 1 by cepharanthine via promoting cellular autophagy through up-regulation of STING/TBK1/P62 pathway.
    Antiviral Res. 2021;193:105143.
    PubMed     Abstract available
    
    
    May 2021
17. HARRISON KS, Jones C
    Wnt antagonists suppress herpes simplex virus type 1 productive infection.
    Antiviral Res. 2021 May 4:105082. doi: 10.1016/j.antiviral.2021.105082.
    PubMed     Abstract available
    
    
    March 2021
18. LUGANINI A, Sibille G, Mognetti B, Sainas S, et al
    Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.
    Antiviral Res. 2021 Mar 11:105057. doi: 10.1016/j.antiviral.2021.105057.
    PubMed     Abstract available
    
    
    
19. HAGEN NR, Nguyen ML, Williams JD, Bowlin TL, et al
    Pentostatin antagonizes the antiviral activity of MBX-2168 by inhibiting the biosynthesis of the active compound.
    Antiviral Res. 2021;187:105018.
    PubMed     Abstract available
    
    
    February 2021
20. ALVAREZ DM, Duarte LF, Corrales N, Smith PC, et al
    Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818].
    Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022.
    PubMed    
    
    
    May 2020
21. KIM HC, Oh DS, Park JH, Kim HJ, et al
    Multivalent DNA vaccine protects against genital herpes by T-cell immune induction in vaginal mucosa.
    Antiviral Res. 2020;177:104755.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Herpes simplex Infection is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: